Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0275 AUD | +10.00% | -.--% | -.--% |
Feb. 26 | Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
2023 | Exopharm to Cut CEO Role Amid Cost Reductions | MT |
Sales 2022 | 4.21M 2.71M | Sales 2023 | 3.39M 2.19M | Capitalization | 3.52M 2.27M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.44M | Net income 2023 | -7M -4.51M | EV / Sales 2022 | 4.6 x |
Net cash position 2022 | 1.1M 711K | Net cash position 2023 | 109K 70.44K | EV / Sales 2023 | 1 x |
P/E ratio 2022 |
-2.03
x | P/E ratio 2023 |
-0.22
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 24.71% |
1 day | +10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Ian Dixon
FOU | Founder | - | 12-12-31 |
Alison Mew
PRN | Corporate Officer/Principal | 66 | 20-09-14 |
David Franks
SEC | Corporate Secretary | 53 | 21-09-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Davies
CHM | Chairman | - | 23-06-21 |
Ian Dixon
FOU | Founder | - | 12-12-31 |
Clarke Barlow
BRD | Director/Board Member | 43 | 23-02-21 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 3.1M | |
-1.78% | 41.36B | |
+43.74% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
-2.67% | 11.82B | |
+24.76% | 11.85B | |
+7.01% | 11.07B |
- Stock Market
- Equities
- EX1 Stock